Formula I Antibiotics Target Staphylococcus Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for antimicrobial resistance, particularly against Staphylococcal species like MRSP and MRSS, face limitations due to low bioavailability and short serum half-life, necessitating the development of new compounds that effectively target these pathogens without affecting S. aureus.
Innovation Solution
Development of compounds with Formula (I), which selectively inhibit Staphylococcus pathogens such as S. schleferi, S. pseudintermedius, and S. chromogenes by targeting the methylerythritol phosphate pathway, offering a composition comprising these compounds or their pharmaceutically acceptable salts with excipients for treatment and prevention of microbial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fosmidomycin or FR900098 are used as single drug therapy, then they show submicromolar inhibition of P. falciparum growth, but they have low bioavailability and short serum half-life
Solution Approach 1:
The patent modifies the chemical structure of fosmidomycin by introducing α,β-unsaturated analogs with specific substituents (R1-R6 groups including alkyl, aryl, and heteroaryl groups) to change pharmacokinetic parameters while maintaining the core DXR inhibitory activity. This structural modification aims to improve serum half-life and bioavailability without sacrificing the antimalarial efficacy.
Solution Approach 2:
The invention creates composite chemical structures by combining the fosmidomycin core scaffold with various aromatic and heterocyclic groups (such as phenyl, pyridyl, thiazolyl groups with different substituents). These composite molecular structures are designed to optimize both pharmacodynamic activity and pharmacokinetic properties simultaneously.
2Adaptability or versatility
If new compounds are developed to target Staphylococcus pathogens, then selectivity against S. schleferi, S. pseudintermedius, and S. chromogenes is achieved, but activity against S. aureus is intentionally avoided
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns (R1-R6 groups) that create localized interactions with target enzymes in Staphylococcus species. The molecular structure is optimized to have high affinity for DXR in S. schleferi, S. pseudintermedius, and S. chromogenes while having lower affinity or different binding characteristics for S. aureus DXR, achieving species-specific selectivity through localized molecular features.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit the growth of S. schleferi, S. pseudintermedius, and S. chromogenes, providing a therapeutic option with improved bioavailability and extended serum half-life, addressing the limitations of existing therapies.
Implementation Method 1
compounds of the present disclosure are not active against S. aureus pathogens but are active against other Staphylococcus pathogens such as S. schleferi, S. pseudintermedius, and/or S. chromogenes
Data Source
AI summary
The present disclosure provides method of treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject, the method comprising administering a compound of Formula (I) as set forth in the specification. In one embodiment, the prokaryotic pathogen belongs to the genus Staphylococcus.